华芢生物,最早成立于2012年,重点针对有医疗需求及市场机会的适应证开发蛋白质药物。主攻方向是发现、开发和商业化伤口愈合的疗法。目前公司围绕血小板衍生生长因子(PDGF)药物展开研发。PDGF是损伤后由血小板分泌的一种生长因子,可促进血管新生、调节炎症并刺激细胞增殖与迁移,从而加速伤口愈合。核心产品包括Pro-101-1(针对烧烫伤)和Pro-101-2(针对“糖足”,即糖尿病足溃疡)。Pro-...
Source Link华芢生物,最早成立于2012年,重点针对有医疗需求及市场机会的适应证开发蛋白质药物。主攻方向是发现、开发和商业化伤口愈合的疗法。目前公司围绕血小板衍生生长因子(PDGF)药物展开研发。PDGF是损伤后由血小板分泌的一种生长因子,可促进血管新生、调节炎症并刺激细胞增殖与迁移,从而加速伤口愈合。核心产品包括Pro-101-1(针对烧烫伤)和Pro-101-2(针对“糖足”,即糖尿病足溃疡)。Pro-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.